CV date	12-10-2019

Part A. PERSONAL INFORMATION

First and Family name	JAVIER DIAZ NIDO		
ID number	00390948V		
Researcher numbers		Researcher ID	L-2371-2013
		Orcid code	0000-0002-0927-7925

A.1. Current position

Name of University/Institution	Universidad Autónoma de Madrid				
Department	Centro de Biología Molecular Severo Ochoa				
Address and Country	Ciudad Universitaria de Cantoblanco. Madrid. 28049				
Phone number	+34 914978710	E-mail	javier.diaznido@uam.es		
Current position	Catedrático Universidad			From	2019
Espec. cód. UNESCO	249003 (Molecular Neurobiology)				

A.2. Education

Degree	University	Year
Degree in Biological Sciences	Universidad Autónoma de Madrid	1984
PhD in Biological Sciences (Molecular Biology)	Universidad Autónoma de Madrid	1988

A.3. Articles, h Index, thesis supervised

Publications: Scopus: 84 (06/10/2019) WoS: 89 (06/10/2019) Google Scholar: 124 (13/10/2019)
http://scholar.google.es/citations?hl=es&user=uh1r4AoAAAAJ&view_op=list_works&sortby=pubdate
http://www.ncbi.nlm.nih.gov/pubmed/?term=%22D%C3%ADaz-Nido+J%22%5BAuthor%5D
Citations: CitasWoS: 9223 (06/10/2019) Scopus: 9082 (06/10/2019)
Google Scholar: 11991 (13/10/2019)
h Index: Google Scholar: 42 (13/10/2019) Scopus: 39 (06/10/2019) WoS: 38 (06/10/2019)
Publications in Q1: 48% WoS **Publications in D1:** 31% WoS
PhD Theses supervised: 9
Nº de Sexenios: 5 (Año último Concedido: 2014)

Part B. CV SUMMARY *(max. 3500 characters, including spaces)*

PhD in Biological Sciences (Molecular Biology Program) by the *Universidad Autónoma de Madrid* (1988). I did a postdoctoral stay at Cold Spring Harbor Laboratory (New York, USA). *Profesor Titular* (Associate Professor) in the Department of Molecular Biology of the *Universidad Autónoma de Madrid* (UAM) since 1995. *Catedrático* (Full Professor) since 2019.

My research work in Neuroscience has been focused on the study of the molecular basis of neurodegenerative diseases. Since 2002 I lead a research group at the *Centro de Biología Molecular Severo Ochoa* (joint center of the UAM and CSIC) which is now focused on the study of Friedreich's ataxia, which is the most common hereditary ataxia in the European population. Our aims are the understanding of the mechanisms underlying neurodegeneration in this pathology and the development of novel therapies for its treatment. Our research group is also associated with the *Instituto de Investigaciones Sanitarias Hospital Puerta de Hierro Majadahonda (IDIPHIM).*

With a very intense teaching activity, I am also committed to the improvement of higher education at UAM. I have participated in the design of the new Bachelor, Master and Doctorate studies at the UAM. I have served as Coordinator of the Degree in Biochemistry, Master in Molecular Biomedicine and PhD Program in Molecular Biosciences of the UAM. I am currently Director of the Doctoral School of the UAM. Very interested in communication, dissemination and scientific extension activities in the field of Biomedicine.

Part C. RELEVANT MERITS

C.1. Recent Relevant Publications

1.- Gene transfer of brain derived neurotrophic factor (BDNF) prevents neurodegeneration triggered by frataxin deficiency. Katsu-Jiménez Y, Loria F, Corona JC, Diaz-Nido J. **Mol Ther.** 2016 May;24(5):877-89. doi: 10.1038/mt.2016.32. Epub 2016 Feb 5.

2.- Delivery of the 135 kb human frataxin genomic DNA locus gives rise to different frataxin isoforms. Pérez-Luz S, Gimenez-Cassina A, Fernández-Frías I, Wade-Martins R, Díaz-Nido J. **Genomics.** 2015 Aug;106(2):76-82. doi: 10.1016/j.ygeno.2015.05.006. Epub 2015 May 28.

3.- Frataxin knockdown in human astrocytes triggers cell death and the release of factors that cause neuronal toxicity. Loría F, Díaz-Nido J. **Neurobiol Dis.** 2015 Apr;76:1-12. doi: 10.1016/j.nbd.2014.12.017. Epub 2014 Dec 29.

4.- Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-like cells. Palomo GM, Cerrato T, Gargini R, Diaz-Nido J. **Hum Mol Genet.** 2011 Jul 15;20(14):2807-22. doi: 10.1093/hmg/ddr187. Epub 2011 Apr 29.

5.- Infectious delivery and long-term persistence of transgene expression in the brain by a 135-kb iBAC-FXN genomic DNA expression vector. Gimenez-Cassina A, Wade-Martins R, Gomez-Sebastian S, Corona JC, Lim F, Diaz-Nido J. **Gene Ther.** 2011 Oct;18(10):1015-9. doi: 10.1038/gt.2011.45. Epub 2011 Apr 14.

6.- Hexokinase II gene transfer protects against neurodegeneration in the rotenone and MPTP mouse models of Parkinson's disease. Corona JC, Gimenez-Cassina A, Lim F, Díaz-Nido J. **J Neurosci Res.** 2010 Jul;88(9):1943-50. doi: 10.1002/jnr.22357.

7.- Mitochondrial hexokinase II promotes neuronal survival and acts downstream of glycogen synthase kinase-3. Gimenez-Cassina A, Lim F, Cerrato T, Palomo GM, Diaz-Nido J. **J Biol Chem.** 2009 Jan 30;284(5):3001-11. doi: 10.1074/jbc.M808698200. Epub 2008 Nov 25.

8.- Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Lim F, Palomo GM, Mauritz C, Giménez-Cassina A, Illana B, Wandosell F, Díaz-Nido J. **Mol Ther.** 2007 Jun;15(6):1072-8. Epub 2007 Mar 20.

9.- Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells. Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, Lim F, Wade-Martins R. **Mol Ther.** 2007 Feb;15(2):248-54.

10.- Gene transfer into Purkinje cells using herpesviral amplicon vectors in cerebellar cultures. Gimenez-Cassina A, Lim F, Diaz-Nido J. **Neurochem Int**. 2007 Jan;50(1):181-8. Epub 2006 Sep 20.

11.- Genes associated with adult axon regeneration promoted by olfactory ensheathing cells: a new role for matrix metalloproteinase 2. Pastrana E, Moreno-Flores MT, Gurzov EN, Avila J, Wandosell F, Diaz-Nido J. **J Neurosci.** 2006 May 17;26(20):5347-59.

C.2. Research projects and grants

1. Ref: B2017/BMD-3700
Title: Metabolic Basis of Neurodegeneration (NEUROMETAB).
PI: Javier Díaz Nido
Funding institution: Consejería de Educación de la Comunidad de Madrid (Programa de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid en Biomedicina).
Duration: 01/01/2018 - 31/12/2019
Funding (in euros): 41.400

2.- Ref: SAF2015-69361-R
Title: Neurodegeneration in Friedreich's ataxia: molecular basis and therapeutical approaches.
PI: Javier Díaz Nido
Funding institution: Dirección General de Investigación. Ministerio de Economía y Competitividad.
Duration: 01/01/2016 – 31/12/2018
Funding (in euros): 145.000

4.- Ref: SAF 2012-38042
Title: Physiopathology and therapy of Friedreich's ataxia.
PI: Javier Díaz Nido
Funding institution: Dirección General de Investigación. Ministerio de Economía y Competitividad.
Duration: 01/01/2013 - 31/12/2015
Funding (in euros): 152.100

3. Ref: S2010/BMD-2331
Title: Signaling networks and effector pathways in animal and cell models of neurodegenerative diseases (NEURODEGMODELS).
PI: Javier Díaz Nido
Funding institution: Consejería de Educación de la Comunidad de Madrid (Programa de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid en Biomedicina).
Duration: 01/01/2012 - 31/12/2015

5. Title: Small molecule neurotrophic receptor agonists as potential therapeutic agents for Friedreich's ataxia
PI: Javier Díaz Nido
Funding institution: Ataxia UK
Duration: 01/04/2014 - 31/03/2015
Funding (in euros): 60.000

6. Title: Development of novel blood-brain barrier-crossing DNA nanocarriers to treat Friedreich's ataxia.
PI: Javier Díaz Nido
Funding institution: Friedreich Ataxia Research Alliance (FARA)
Duration: 01/01/2014 – 31/12/2015
Funding (in euros): 60.000

7. Ref: SAF 2009-10757
Title: Neurodegeneration and molecular therapy in Friedreich's ataxia models.
PI: Javier Díaz Nido
Funding institution: Dirección General de Investigación. Ministerio de Ciencia e Innovación.
Duration: 01/01/2010 – 12/31/2012
Funding (in euros): 200.860

8. Ref: S-SAL-0202-2006
Title: Molecular mechanisms of neurodegeneration: animal and cell models.
PI: Javier Díaz Nido
Funding institution: Consejería de Educación de la Comunidad de Madrid (Programa de Actividades de I+D entre Grupos de Investigación de la Comunidad de Madrid en Biociencias).
Duration: 01/01/2007 – 31/12/2010
Funding (in euros): 120.900

C.4. Patents

USE OF CARBAMYLATED ERYTHROPOIETIN FOR THE TREATMENT OF FRIEDREICH'S ATAXIA . PCT/DK2010050285
10-26-2010

REVERSIBLY IMMORTALISED OLFACTORY ENSHEATHING GLIA AND THEIR USE TO PROMOTE NEURONAL REGENARATION. PTC/GB2004003149
07-19-2004.

C.5. Institutional responsibilities.

Coordinator of the Neurochemistry Group of the Spanish Society of Biochemistry and Molecular Biology (SEBBM) from 2001 to 2004.

Member of the National Drafting Commission of the "White Paper on Undergraduate and Postgraduate Degrees in Biochemistry and Biotechnology" (project funded by the National Agency for the Evaluation of Quality and Accreditation, ANECA, from October 2004 to December 2005) .

Coordinator of the Degree in Biochemistry of the UAM (since June 2004 to April 2008) and Delegate of the Dean for the Degree of Biochemistry (from April 2008 to October 2009).

President of the Conference of Coordinators of the Degrees in Biochemistry and Biotechnology of Spanish Universities (from September 2006 to September 2009).

Coordinator of the Official Postgraduate Program in Molecular Biosciences at the UAM (from February 2007 to November 2013).

Director of the Master in Molecular Biomedicine at the UAM (from February 2007 to April 2012).

Coordinator of the PhD Program in Molecular Biosciences of the UAM (from April 2012 to October 2013).

Delegate of the Rector for Doctoral Schools of the UAM (from November 2013 to March 2016).

Director of the Doctoral School of the UAM (since March 2016).